Search Results

You are looking at 131 - 140 of 858 items for :

  • Refine by Access: All x
Clear All
Full access

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer

Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force

Tumor Size: Tumor size is a well-established independent prognostic factor for breast cancer, with the risk of relapse increasing as tumor size increases, regardless of axillary lymph node status ( Table 1 ). 5 , 6 Recent Surveillance, Epidemiology, and

Full access

HSR19-106: Association Between Pathological Complete Responses and Long-Term Survival Outcomes Among Triple-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Cynthia Z. Qi, Min Huang, Amin Haiderali, Jipan Xie, Zheng-Yi Zhou, Eric Q. Wu, and Peter Fasching

=19), disease-free survival (DFS; N=14), relapse-free survival (RFS; N=7), event-free survival (N=5), distant DFS (N = 4), and local RFS (N=2). Kaplan-Meier analysis was used to assess the association between pCR and these outcomes in 31 studies. Clear

Full access

QIM19-134: Improving Access to Bone Marrow Transplant in the Community: The Memorial Sloan Kettering Cancer Alliance Shared Care Program

Craig Sauter, W. Jeffrey Baker, Elizabeth Rodriguez, Silvia Willumsen, Barbara Morcerf, Kristi Gafford, Jessica Kennington, Richard Korman, Peter Yu, David Pfister, and Sergio Giralt

like infectious disease and dermatology; and research, including an MSK clinical trial open at HHC to identify and understand barriers to transplant in the community for patients with newly diagnosed or relapsed acute leukemia. Results: Since November

Full access

HSR19-084: Real-World Treatment Patterns and Clinical Outcomes in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations

Maral DerSarkissian, Shuanglian Li, Aaron Galaznik, Rachel Bhak, Iryna Bocharova, Thomas Kulalert, Huamao M. Lin, Hui Huang, and Mei Sheng Duh

: Flatiron Health electronic health record data, largely from community oncology practices, from January 2011–April 2018 were used for this retrospective observational study. Treatment-naïve (TN) and relapsed/refractory (RR) second-line patients diagnosed

Full access

HSR19-107: Nivolumab for Newly Diagnosed Classical Hodgkin Lymphoma: Patient-Reported Outcomes From CheckMate 205 Cohort D

Radhakrishnan Ramchandren, Stephen M. Ansell, Philippe Armand, Andreas Engert, Fiona Taylor, Kim Cocks, Clara Chen, Bryan Bennett, Alejandro Moreno-Koehler, Adam Roeder, Anne Sumbul, Mariana Sacchi, and David Cella

checkpoint inhibitor monoclonal antibody, demonstrated efficacy and clinically meaningful improvement in pt-reported outcomes (PROs) in pts with relapsed/refractory cHL in cohorts A, B, and C of CheckMate 205 (NCT02181738) (Armand et al, J Clin Oncol 2018

Full access

EPR19-070: Incidence Pattern of Malignant Lymphoma by Cell-Lineage/Cell-Maturity Status in Nagasaki, Japan, 1985–2012: Preliminary Results

Thi My Hanh Luong, Daisuke Niino, Hisayoshi Kondo, Shiro Miura, Masahiro Nakashima, and Masako Iwanaga

Nagasaki Prefectural Cancer Registry. From those, we excluded 1,477 records because of codes other than ML, diagnosed before 1985, and possible relapse records of identical cases. Records based on ICD-O-1 or ICD-O-2 were substituted by the corresponding ICD

Full access

YIA19-002: Axl-RTK Inhibition Modulates T Cell Functions and Synergizes With Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies

Saad S. Kenderian, Reona Sakemura, Nan Yang, Michelle Cox, Sutapa Sinha, Mehrdad Hefazi, Michael Hansen, Kendall Schick, Cynthia Forsman, Justin Boysen, Wei Ding, Sameer Parikh, and Neil Kay

reduction in Tregs, reduction of inhibitory receptors and polarization to a Th1 phenotype. These findings will be further investigated in a planned phase 1 clinical trial of TP0903 in relapsed/refractory CLL (NCT03572634) In summary, we demonstrated for the

Full access

Beyond BCR::ABL1—The Role of Genomic Analyses in the Management of CML

Susan Branford, Adelina Fernandes, NurHezrin Shahrin, Muneeza Maqsood, Naranie Shanmuganathan, and Carol Wadham

–KMT2A binding interaction, revumenib, has recently received FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory acute leukemia with KMT2A rearrangement. 54 Complete remission was achieved in 30% of patients

Full access

Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr., Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Jose M. Pacheco, Sandip P. Patel, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina Gregory, and Miranda Hughes

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer. This selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastatic NSCLC and actionable mutations.

Full access

Non–Small Cell Lung Cancer, Version 4.2024

Gregory J. Riely, Douglas E. Wood, David S. Ettinger, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Aakash P. Desai, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aditya Juloori, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Trey C. Mullikin, Thomas Ng, Dawn Owen, Dwight H. Owen, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Jonathan Riess, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, and Lisa Hang

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable molecular biomarkers.